New study tracks Real-World use of vimseltinib for rare tumor
NCT ID NCT07075471
First seen Nov 06, 2025 · Last updated May 24, 2026 · Updated 25 times
Summary
This study observes 100 people with tenosynovial giant cell tumor (TGCT) who are taking vimseltinib as part of their normal care. Researchers will collect data on how long patients stay on the drug and how it affects their quality of life. No extra treatments or changes to care are involved.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TENOSYNOVIAL GIANT CELL TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Synexus Clinical Research, US INC
RECRUITINGWilmington, North Carolina, 28401, United States
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.